伏索利肽
伏索利肽是一種用於治療軟骨發育不全症的藥物。[1]伏索利肽由拜瑪林製藥研發。 [1][2][3][4]
有患者在注射伏索利肽後注射部位會腫脹、瘙癢、發紅或疼痛，還有患者會嘔吐和血壓下降。這些都是常見的副作用 [1]
2021年8月，伏索利肽在歐盟國家獲批上市[1][5][2] ，並於2021年11月在美國獲批上市 [6]。伏索利肽在美國和歐盟具有孤兒藥地位。 [1][2][3][4]
參考文獻
[編輯]- ^ 1.0 1.1 1.2 1.3 1.4 Voxzogo EPAR. European Medicines Agency. 23 June 2021 [9 September 2021]. （原始內容存檔於10 September 2021）.
- ^ 2.0 2.1 2.2 European Commission Approves BioMarin's Voxzogo (vosoritide) for the Treatment of Children with Achondroplasia from Age 2 Until Growth Plates Close (新聞稿). BioMarin Pharmaceutical. 27 August 2021 [9 September 2021]. （原始內容存檔於28 August 2021）.
- ^ 3.0 3.1 Food and Drug Administration Accepts BioMarin's New Drug Application for Vosoritide to Treat Children with Achondroplasia (新聞稿). BioMarin Pharmaceutical. 2 November 2020 [9 September 2021]. （原始內容存檔於10 September 2021）.
- ^ 4.0 4.1 Advancing Health Through Innovation: New Drug Therapy Approvals 2021. U.S. Food and Drug Administration (FDA) (報告). 13 May 2022 [22 January 2023]. （原始內容 (PDF)存檔於6 December 2022）.
- ^ Voxzogo Product information. Union Register of medicinal products. [3 March 2023]. （原始內容存檔於4 March 2023）.
- ^ BioMarin Receives FDA Approval for Voxzogo (vosoritide) for Injection, Indicated to Increase Linear Growth in Children with Achondroplasia Aged 5 and Up with Open Growth Plates (新聞稿). BioMarin Pharmaceutical. 19 November 2021 [19 November 2021]. （原始內容存檔於6 August 2022）.